7-Methoxytryptamine (7-MeO-T or 7-methoxy-T; developmental code name PAL-533) is a serotonin receptor modulator and monoamine releasing agent of the tryptamine family. It is the 7-methoxy derivative of tryptamine.
The drug acts as a full agonist of the serotonin 5-HT2A receptor, with an of 496nM and an of 107%. It shows 67-fold lower potency as a serotonin 5-HT2A receptor agonist compared to tryptamine itself. In addition to its serotonin 5-HT2A receptor agonism, 7-methoxytryptamine is a serotonin releasing agent (SRA), with values for induction of monoamine release of 44.6nM for serotonin, 2,118nM for dopamine, and 5,600nM for norepinephrine in rat brain synaptosomes. The effects of 7-methoxytryptamine in rodents have been described.
Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives. However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans.
The chemical synthesis of 7-methoxytryptamine has been described.
7-Methoxytryptamine was first described in the scientific literature by Ernst Späth and Edgar Lederer by 1931. Its pharmacology was subsequently assessed in greater detail in 2014.
See also Substituted tryptamine 7-MeO-DMT 7-MeO-DiPT 7-MeO-MiPT 7-Hydroxytryptamine 7-Methyltryptamine
References
External links 7-MeO-T - Isomer Design